Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01996384 |
|
Recruitment Status :
Completed
First Posted : November 27, 2013
Last Update Posted : October 6, 2017
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Provoked, Localized Vulvodynia Provoked Vestibulodynia Vulvar Vestibulitis Vulvodynia | Procedure: Classical Acupuncture Procedure: Non-classical acupuncture Drug: Lidocaine | Phase 1 |
This is a randomized, controlled, single-blinded, pilot trial to study the feasibility and acceptability of acupuncture and 5% lidocaine. Patients will be recruited from the patient population of the Oregon Health & Science University Vulvar Health Clinic. Thirty (30) patients with PLV will be enrolled as study participants into the study. Fifteen (15) will be allocated in the treatment (classical) acupuncture + 5% lidocaine group and fifteen (15) will be allocated in the control (non-classical) acupuncture + 5% lidocaine group via a computer generated randomization program to balance allocation based on four variables: pain intensity, smoking status, body mass index, and pain duration.
The acupuncturist will interview each patient and perform an exam of the pulse and tongue. A standardized acupuncture treatment will be assigned, and both groups will receive 18 acupuncture treatments that follow a standardized protocol on classical or non-classical acupuncture points, with or without mild electrical stimulation. All study participants will self-apply lidocaine cream to their genital region four times daily during the study.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 19 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Acupuncture Augmentation of Lidocaine for the Treatment of Provoked, Localized vulvodynia-a Feasibility and Acceptability Pilot Study |
| Study Start Date : | November 2013 |
| Actual Primary Completion Date : | March 2016 |
| Actual Study Completion Date : | March 2016 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Classical Acupuncture + Lidocaine
Study participants will attend 18 classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area based on up to three Traditional Chinese Medicine Diagnosis categories. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
|
Procedure: Classical Acupuncture
Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States. Drug: Lidocaine Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
Other Name: 5% Lidocaine cream |
|
Active Comparator: Non-classical acupuncture + lidocaine
Study participants will attend 18 non-classical acupuncture sessions, twice a week for Weeks 1-6, and once a week for Weeks 7-12. A standardized acupuncture treatment will be assigned with non-classical acupuncture points and may or may not be stimulated with electroacupuncture. Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. Study participants will also be asked to gently apply 5% lidocaine cream four times daily (breakfast, lunch, dinner, and before bed).
|
Procedure: Non-classical acupuncture
Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States. Drug: Lidocaine Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
Other Name: 5% Lidocaine cream |
- Tampon Test [ Time Frame: Weeks 1 and 12 study period ]
Primary outcome variable will be to measure the change in the reported pain of the "Tampon Test" (mean at Week 1) to the reported pain of "Tampon Test" (mean of Week 12);
Every week, study participants will be asked to fully insert and remove a tampon and rate the level of pain with insertion on a 10-point Visual Analog Scale (0 indicating no pain, 10 indication worst possible pain).
- Cotton Swab test [ Time Frame: Weeks -4, -3, -2, -1, 0, 1, 12 or 13 and 24. ]
Secondary outcome variable will compare the "Cotton Swab Test" with a blinded assessor reported pain at three timepoints. 1) change in reported pain at (mean at Weeks -2, -1, 0, and 1) to the reported pain (mean at Weeks 12 and 13; 2) change in reported pain (means Weeks -2, -1, 0, and 1) to the reported pain (mean at Week 24); 3) change in reported pain (mean at Week 12) to (mean at Week 24).
Vestibular tenderness will be assessed by light touch with a cotton swab by a blinded assessor to the study participant's: 1) vestibule (cotton swab test) at four defined points (1:00, 5:00, 7:00, and 11:00); 2) the perineum; 3) labia majora (2:00 and 8:00), and 4) labia minora (4:00 and 10:00). Tenderness at each location will be rated by the Study Participant on a 10-point scale (0 indicating no pain, 10 indicating worst possible pain).
- Patient Reported Outcomes Measurement Information System (PROMIS) Scales [ Time Frame: At baseline visit, 6 weeks, 12 weeks, and 24 weeks ]Assess changes in scores quality of life, vaginal discomfort, pain intensity, pain interference and behavior, anxiety, and depression at 6 weeks, 12 weeks, and 24 weeks compared to baseline.
- Satisfaction [ Time Frame: Weeks 12 and 24 ]Using 5-point scales (Very satisfied, satisfied, neither satisfied nor dissatisfied, dissatisfied, Very dissatisfied), Study participants will be asked how satisfied they are with the study interventions and how satisfied they are with their pain relief.
- Expectation [ Time Frame: Week 1 ]Study participants will be asked about how much they 'expect' the study interventions will or will not help, how much they 'think' the intervention will or will not help, and how much they 'feel' about the intervention will or will not help via 10-point scales.
- Feasibility [ Time Frame: Weeks 12 and 24 ]Assess feasibility by the number of study participants enrolled.
- Acceptability [ Time Frame: Weeks 12 and 24 ]Assess acceptability by the number of study visits attended by participants enrolled.
- Tampon Test [ Time Frame: Weeks 1 and 6; Weeks 1 and 24 ]
Secondary outcome variables will be to:
- measure the change in reported pain of the "Tampon Test" (mean at Week 1) to the reported pain of "Tampon Test" (mean of Week 6);
- measure the change in reported pain of the "Tampon Test" (mean at Week 1) to the reported pain of "Tampon Test" (mean of Week 24);
- measure the change in reported pain of the "Tampon Test" (mean at Week 12) to the reported pain of "Tampon Test" (mean of Week 24).
Every week, study participants will be asked to fully insert and remove a tampon and rate the level of pain with insertion on a 10-point Visual Analog Scale (0 indicating no pain, 10 indication worst possible pain).
- Traditional Chinese Medicine (TCM) Diagnosis Category [ Time Frame: Week 1 ]TCM Diagnosis Category will be recorded and tracked by the primary investigator to determine if it may be a potential predictor of treatment response.
- 24-hour mean pain score [ Time Frame: Baseline, Weeks 6, 12, and 24 ]In a daily pain diary, study participants will be asked to record the level of pain they are experiencing based via the 10-point VAS scale (0 indicates no pain, 10 indicates worst possible pain).
- Frequency of intercourse [ Time Frame: Baseline, Weeks 6, 12, and 24 ]In a daily pain diary, study participants will be asked to record if they engaged in intercourse within the last 24 hours.
- Intensity of Intercourse pain [ Time Frame: Baseline, Weeks 6, 12, and 24 ]In a daily pain diary, study participants will be asked to record the level of pain they are experienced with intercourse based via the 10-point VAS scale (0 indicates no pain, 10 indicates worst possible pain).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 45 Years (Adult) |
| Sexes Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Literate, English speaking, premenopausal, women meeting Friedrich's criteria for Provoked, localized vulvodynia
- Reported introital dyspareunia longer than three months duration;
- Average pain score greater than 4 on Visual Analog Scale (VAS) at enrollment with cotton swab test and Tampon Test;
- Able to insert an Original Regular Tampax™ tampon.
Exclusion Criteria:
- Co-existing conditions leading to dyspareunia including generalized unprovoked vulvodynia, atrophic vaginitis, vulvovaginal dermatoses (e.g. lichen sclerosus), or genital infection (e.g. herpes simplex virus or yeast infection).
- Pregnant or postpartum and breastfeeding;
- Use of neuromodulator medications (e.g. Serotonin Norepinephrine Reuptake Inhibitors (SNRIs), Tricyclic Antidepressants, or anti-seizure medications) started in the last six months. If taken for longer, must be on a stable dose for at least six months and still report moderate to severe pain. Selective Serotonin Reuptake Inhibitors (SSRIs) are allowed;
- Postmenopausal as defined by surgical or natural menopause (no menses for 12 months);
- Chronic pelvic pain defined as daily, non-menstrual pain in pelvis or lower abdomen for longer than three months duration;
- Must be able to refrain from other treatments for PLV including non-traditional options (e.g. other medications, physical therapy, sex therapy, acupuncture, naturopathic remedies) during the course of the study (6 months).
- Use of SNRIs, lidocaine, or acupuncture within the last three months.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01996384
| United States, Oregon | |
| Women's Health Research Unit; Oregon Health & Science University | |
| Portland, Oregon, United States, 97239 | |
| Principal Investigator: | Lee E Hullender Rubin, DAOM | Oregon College of Oriental Medicine |
Additional Information:
Publications of Results:
| Responsible Party: | Lee Hullender Rubin, DAOM, LAc, Adjunct Research Faculty, Oregon College of Oriental Medicine |
| ClinicalTrials.gov Identifier: | NCT01996384 History of Changes |
| Other Study ID Numbers: |
OHSU IRB 9664 |
| First Posted: | November 27, 2013 Key Record Dates |
| Last Update Posted: | October 6, 2017 |
| Last Verified: | October 2017 |
Keywords provided by Lee Hullender Rubin, DAOM, LAc, Oregon College of Oriental Medicine:
|
Vulvodynia Provoked, localized vulvodynia vulvar pain vulvar vestibulitis provoked vestibulodynia vulvovaginal pain vaginal pain chronic pain lidocaine numbing agent anesthetic cream acupuncture electroacupuncture electrical stimulated acupuncture manual acupuncture |
classical acupuncture non-classical acupuncture Traditional Chinese Medicine TCM Chinese medicine Acupuncture and Oriental Medicine AOM treatment feasibility pilot study Patient Reported Outcomes Measure Information System Tampon Test cotton swab test pain diary Research Electronic Data Capture |
Additional relevant MeSH terms:
|
Vulvodynia Vulvar Vestibulitis Vulvar Diseases Genital Diseases, Female Vulvitis Lidocaine Anesthetics, Local Anesthetics Central Nervous System Depressants |
Physiological Effects of Drugs Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Voltage-Gated Sodium Channel Blockers Sodium Channel Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action |